Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOR-SWITCH: Switching from Remicade to Remsima
NCT02148640Phase 4Completed
- Sponsor
- Diakonhjemmet Sykehus
- Start
- Oct 2014
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA), ulcerative colitis (UC), Crohn's disease, sponsored by Diakonhjemmet Sykehus. Started Oct 2014; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)spondyloarthritis (SpA)psoriatic arthritis (PsA)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02148640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148640.